Press Releases

Veteran Clinical Research Executive Steve Clemons Joins ObjectiveHealth as CEO

ObjectiveHealth, a Nashville-based integrated research and technology platform company, announced today that veteran clinical research executive Steve Clemons has joined the company as CEO.

Peak Heart & Vascular Launches Exclusive Research Partnership with Axsendo Clinical Research

About Peak Heart & Vascular Peak Heart & Vascular is a leading cardiovascular practice serving the Phoenix metropolitan area and Northern Arizona, dedicated to providing comprehensive heart and vascular care. Founded by a team of highly seasoned, board-certified cardiologists, electrophysiologists, and vascular surgeons, the practice is highly regarded within the community and has been awarded for excellence in patient care, innovation, and research. In addition to its clinical offices, Peak Heart & Vascular operates state-of-the-art outpatient surgery centers, offering patients access to minimally invasive procedures in a convenient and cost-effective setting. These centers have earned The Joint Commission’s Gold Seal of Approval ® Accreditation, ensuring the highest standards of safety and care. Learn more at peakheart.com. About Axsendo Clinical Research Axsendo Clinical Research is a leading clinical research organization dedicated to advancing medical science through innovative clinical trials. With a focus on bringing research opportunities closer to diverse communities, Axsendo partners with healthcare providers across multiple specialties to improve patient access to cutting-edge treatments. For more information, visit www.axsendoclinicalresearch.com. For more information: Peak Heart & Vascular Shawn Smith media@peakheart.com 602.698.7325 Axsendo Clinical Research info@axsendoclinical.com 844.290.2273

Caidya Announces $165 Million Strategic Growth Investment From Rubicon Founders

Caidya today announced the closing of a strategic growth investment of $165 million from funds managed by Rubicon Founders.

Chromatin Bioscience’s synthetic promoter supports EsoBiotec’s ESO-T01 CAR-T therapy as it enters the clinic

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antigen (BCMA) CAR-T candidate to reach the clinical stage and utilises a synthetic promoter designed using Chromatin Bio’s proprietary promoter design platform, chromatinLENS, exclusively for EsoBiotec as part of its innovative approach to immunotherapy.

Coronado Research announce appointment of Jo Marshall as EVP Data Services and Advanced Analytics

Coronado Research is pleased to announce the appointment of Jo Marshall as EVP of Data Services and Advanced Analytics.

Biofidelity and CellCarta partner to deploy Aspyre® Lung in global clinical trials

Biofidelity and CellCarta have announced a strategic partnership agreement to utilize Biofidelity’s Aspyre® Lung in global clinical trials.

STEMart Announces Balloon Catheter Testing Services to Ensure Medical Device Safety and Regulatory Compliance

STEMart introduces Balloon Catheter Testing Services for the development of safe and effective medical devices.

Kindeva Drug Delivery and Emervax Partner To Bring Game Changing Vaccine Administration to Patients

PrecisionLife Appoints Bill Keating as Chief Commercial Officer, Diagnostics and Healthcare

PrecisionLife announces the appointment of Bill Keating as Chief Commercial Officer, Diagnostics and Healthcare.

ClearNote Health’s Avantect® Multi-Cancer Detection Test Selected as One of Two Noninvasive Blood-Based Technologies for National Cancer Institute’s Vanguard Study

ClearNote Health announced that its Avantect Multi-Cancer Detection Test was selected for the National Cancer Institute’s new Vanguard Study.

Quris-AI's Bio-AI Platform Integrated by Merck KGaA, Darmstadt, Germany for Preclinical Small Molecule Drug Safety Evaluation

Following an expanded collaboration between AI innovator Quris-AI and Merck KGaA and a two-year validation study to test clinical safety prediction by identifying drug candidate liver toxicity risks, it was announced this morning that Merck KGaA has adopted the startup's platform to test small molecule drug candidates prior to initiating clinical trials. Quris-AI’s platform integrates advanced AI, machine learning, generative models, patient-on-chip technology, and proprietary data to predict potential drug-induced toxicities better.

IDDI (International Drug Development Institute) Announces New Leadership to Drive Growth and Innovation

IDDI, a Belgium-based clinical research service provider with a U.S. office in Raleigh, NC, has announced significant changes to its executive leadership team. Tim Davis has been appointed as CEO, bringing over 25 years of expertise in pharmaceuticals, life sciences, and digital health. Jeremy Edwards has been named the new Chief Commercial Officer at IDDI bringing 27 years of experience across the clinical development continuum. Davis and Edwards’ combined expertise will strengthen IDDI’s operational excellence and patient-centric solutions. The new leadership positions IDDI for growth, focusing on delivering integrated patient-relevant outcomes across clinical trial phases for clients in the USA and Europe. www.iddi.com

ActiGraph accelerates clinical trial modernization with transformational acquisition of Biofourmis life science business

ActiGraph, the global leader in wearable digital health technology for clinical research and development, has announced the acquisition of Biofourmis Connect, a division of Biofourmis that delivers an AI-driven, digital trial platform tailored for the life science industry.

ClearNote Health’s Avantect® Test Selected for World’s Largest Study of Pancreatic Cancer Detection in High-Risk Patient Population

ClearNote Health's Avantect Pancreatic Cancer test was selected for a large UK NHS study that will include up to 15,000 patient participants recently diagnosed with type 2 diabetes. The Avantect test is a blood-based assay designed to use key epigenomic and genomic signals to detect the earliest indicators of pancreatic cancer.

Oxford Nanopore, Action for ME, and University of Edinburgh launch groundbreaking study into the genetics of ME

Oxford Nanopore Technologies will participate in a groundbreaking study will analyse the entire genetic code of up to 17,000 people with Myalgic Encephalomyelitis (ME) in a bid to uncover the genetic causes of the illness.

eClinical Solutions Collaborates with Snowflake to Streamline Data for Life Sciences

Integration between eClinical’s elluminate Clinical Data Cloud and Snowflake offers modern data architecture to power clinical data science and AI, unlock data value for healthcare outcomes

ENEA-Tech Biomedical Foundation invests €6m in BetaGlue® Therapeutics brings 2024 funding round total to €24m

BetaGlueBetaGlue announced today that the ENEA-Tech and Biomedical Foundation has invested €6m bringing the total raised in the current funding round to €24m.

Coronado Research announce appointment of Dr Jennifer Bradford as VP, Head of Data Science

Coronado Research announced today that Dr Jennifer Bradford has been appointed as VP, Head of Data Science.

VieCure’s Halo Intelligence Platform Adopted by Commonwealth Cancer Center

VieCure announced that Commonwealth Cancer Center will deploy its Halo Intelligence platform - the first AI-enabled community oncology care solution. Clinicians will use the platform to manage precision oncology data and help determine the optimal personalized treatment path for patients across rural Kentucky.

The Institute of Tissue Medicine of the University of Bern Chooses Indica Labs’ HALO AP® to Become the First Public Health Institute in Switzerland to Deploy Digital Pathology for Diagnostics in the Cloud with Amazon Web Services (AWS)

Indica Labs today announces that the Institute of Tissue Medicine and Pathology at the University of Bern has selected HALO AP® for the Institute’s first-in-country digital pathology deployment in the cloud powered by Amazon Web Services, Inc.